| Literature DB >> 35013785 |
Michael Schwaiger1, Sarah-Jayne Edmondson2, Jasmin Rabensteiner3, Florian Prüller3, Thomas Gary4, Wolfgang Zemann1, Jürgen Wallner5.
Abstract
OBJECTIVE: The objectives of this prospective cohort study were to establish gender-related differences in blood loss and haemostatic profiles associated with bimaxillary surgery. In addition, we aimed to identify if any gender differences could be established which might help predict blood loss volume.Entities:
Keywords: Blood loss; Gender; Haemostasis; Orthognathic surgery
Mesh:
Substances:
Year: 2022 PMID: 35013785 PMCID: PMC8979869 DOI: 10.1007/s00784-021-04347-z
Source DB: PubMed Journal: Clin Oral Investig ISSN: 1432-6981 Impact factor: 3.573
Fig. 1Figure to show the study design of this prospective cohort study
The formulae used to calculate blood loss in this present study [6, 22]
| Blood loss calculation | ||
|---|---|---|
| Subtraction method | IOB = fluid in suction cannister − irrigation fluid + weight difference in swabs and throat-pack | IOB = Intraoperative blood loss (ml) |
| Haemoglobin-balance method | Hbloss total = TBV × (Hbpre − Hbpost) × 0.001 + Hbt CBL = 1000 × (Hbloss total/Hbpre) | TBV = total blood volume (ml) Hb = haemoglobin (g/L) t = blood transfusion 1 unit banked blood contains 52 g (± 5.4) haemoglobin CBL = calculated blood loss (ml) |
Nadler’s formula, which was used to estimate the patient’s total blood volume [23]
| Estimated total blood volume (TBV) | ||
|---|---|---|
| Nadler’s formula | TBV male 0.3669 × H3 + 0.03219 × W + 0.6041 TBV female 0.3561 × H3 + 0.03308 × W + 0.1833 | TBV = total blood volume H = height (m) W = bodyweight (kg) |
Table to show the haemostatic parameters assessed in this study
| Preoperative coagulation analysis | |||
|---|---|---|---|
| Routine coagulation assays | Global coagulation assay | Specific coagulation analysis | |
aPTT PT INR | Endogenous thrombin potential (%) | ETP_A AUC | Von Wilebrand factor-antigen Von Wilebrand factor-activity Fibrinogen Antithrombin-III Factor VIII Factor IX Factor XI Factor XIII |
| ETP_B AUC | |||
| Peak height of thrombin (%) | ETP_A cmax | ||
| ETP_B cmax | |||
Fig. 2Figure to display the amount of the intraoperative blood loss (IOB) detected according to patient gender. No statistically significant gender-specific differences were found to occur
Gender-specific analysis of the intra- and perioperative blood loss related to bimaxillary surgery
| Intraoperative blood loss (IOB) | m | 603.86 | 254.85 | 600 | 455 | |
| f | 463.13 | 263.25 | 452.5 | 311 | ||
| Calculated blood loss (CBL-48 h) | m | 907.73 | 246.15 | 912.31 | 381.17 | |
| f | 730.82 | 274.54 | 661.78 | 407.89 |
Fig. 3Figure displaying statistically significant gender-specific differences with regard to perioperative blood loss determined 48 h postoperatively (m > f, p = 0.019)
Gender-specific analysis of the haemostatic profile. Females were shown to present with significantly lower levels of Antithrombin-III when compared with males (p = 0.015)
| Preoperative coagulation analysis | ||||||
|---|---|---|---|---|---|---|
| Gender | Mean | SD | Median | IQR | ||
| Routine coagulation assays | ||||||
| aPTT | m | 29.25 | 3.03 | 28.85 | 5.85 | |
| f | 27.69 | 3.58 | 27.7 | 4.60 | ||
| PT | m | 101.77 | 14.16 | 103.5 | 17.00 | |
| f | 104.37 | 11.10 | 103 | 19.75 | ||
| INR | m | 0.99 | 0.09 | 0.97 | 0.08 | |
| f | 0.97 | 0.07 | 0.98 | 0.09 | ||
Global coagulation assay | ||||||
| ETP_A_ AUC (%) | m | 0.86 | 0.21 | 0.89 | 0.10 | |
| f | 0.93 | 0.17 | 0.96 | 0.17 | ||
| ETP_B_AUC (%) | m | 0.85 | 0.12 | 0.85 | 0.13 | |
| f | 0.87 | 0.18 | 0.91 | 0.15 | ||
| ETP_A_thrombin peak height (%) | m | 1.04 | 0.24 | 0.99 | 0.18 | |
| f | 0.96 | 0.21 | 0.99 | 0.19 | ||
| ETP_B_thrombin peak height (%) | m | 0.96 | 0.12 | 0.96 | 0.21 | |
| f | 0.95 | 0.14 | 0.99 | 0.21 | ||
| Specific coagulation analysis | ||||||
| vWF-Ag | m | 102.05 | 38.66 | 107 | 72 | |
| f | 88.58 | 33.31 | 89 | 52 | ||
| vWF-act | m | 110.00 | 76.14 | 90 | 99 | |
| f | 80.23 | 34.37 | 75 | 43 | ||
| Fibrinogen | m | 231.47 | 75.32 | 204 | 61 | |
| f | 244.06 | 76.62 | 237 | 135 | ||
| Antithrombin-III | m | 106.11 | 8.60 | 106 | 15 | |
| f | 96.19 | 15.69 | 100 | 22 | ||
| FVIII | m | 83.61 | 50.77 | 69 | 46 | |
| f | 67.20 | 28.58 | 65.8 | 37 | ||
| FIX | m | 102.76 | 22.39 | 97.4 | 35 | |
| f | 90.83 | 19.46 | 90.8 | 24 | ||
| FXI | m | 97.16 | 27.75 | 105 | 31 | |
| f | 98.16 | 30.28 | 96 | 25 | ||
| FXIII | m | 115.82 | 27.67 | 116 | 53 | |
| f | 121.97 | 23.62 | 122 | 45 |
Fig. 4Figure to depict statistically significant gender-specific differences regarding the level of Antithrombin-III measured on the day prior to surgery (m > f, p = 0.015)
Fig. 5Figure to show the significant positive correlation determined between the level of Antithrombin-III and CBL-48 h (r = 0.474; p = 0.001)
Table to show the statistically significant positive correlations determined in this present study
| Correlation analysis | ||
|---|---|---|
| IOB | CBL-48 h | |
| Antithrombin-III | ||
| Operating time | r = 0.307 | |
Linear regression analysis showing that AT-III was most closely associated with the amount of CBL-48 h. In terms of IOB, the operating time was found to be relevant
| Linear regression analysis | ||
|---|---|---|
| IOB | CBL-48 h | |
| Age | ||
| BMI | ||
| Operating time | ||
| Antithrombin-III | ||
| FIX | ||
| Gender | ||
| ASA-status | ||
| 37% | 35% |